Riskpilot← Back to searchSign inGet full accessNATURE PHARMA NORGE AS
ASActiveOrg 925924512Bekkeveien 163, 3173 VearRetail sale of other food · NACE 4727Est. 20201 employees
Revenue 2025
NOK 79,3M
+73% vs 2024
EBITDA margin
29.4%
+191% vs 2024
Equity ratio
67.1%
Financial strength
Net profit 2025
NOK 18,6M
+190% vs 2024
| Revenue | NOK 79,3M | +73% |
| EBITDA | NOK 23,3M | +191% |
| Net profit | NOK 18,6M | +190% |
| Total assets | NOK 28,4M | +70% |
| Equity | NOK 19M | +82% |
| Employees | 1 | — |
Legal name
NATURE PHARMA NORGE AS
Org number
925924512
Legal form
Aksjeselskap
NACE code
4727 · Retail sale of other food
Founded
6. november 2020
Share capital
NOK 80 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Handel innenfor helsekost- og naturprodukter, samt andre produkter/tjenester som står i naturlig forbindelse med dette, herunder deltakelse i andre selskaper.
Address
Bekkeveien 163, 3173 Vear
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 392 | 8 853 | 28 067 | 45 882 | 79 261 |
| Staff expenses | −0 | −98 | −276 | −359 | −397 |
| EBITDA | 82 | 669 | 4 508 | 8 021 | 23 333 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 82 | 669 | 4 508 | 8 021 | 23 333 |
| Net financials | −0 | −2 | −125 | 185 | 482 |
| Profit before tax | 82 | 667 | 4 383 | 8 206 | 23 815 |
| Tax | 37 | 206 | 883 | 1 812 | 5 244 |
| Net profit | 45 | 460 | 3 500 | 6 394 | 18 571 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 201 | 2 597 | 7 254 | 16 659 | 28 377 |
| Equity | 105 | 566 | 4 065 | 10 459 | 19 030 |
| Long-term debt | 820 | 820 | 0 | 725 | 1 299 |
| Short-term debt | 276 | 1 211 | 3 189 | 5 475 | 8 048 |
| Total debt | 1 096 | 2 031 | 3 189 | 6 200 | 9 347 |
EBITDA margin
29.4%
This company
15.8%
Market median
+86% vs market
20212025
Equity ratio
67.1%
This company
38.2%
Market median
+76% vs market
20212025
Return on equity
97.6%
This company
18.4%
Market median
+430% vs market
20212025
Net profit margin
23.4%
This company
8.1%
Market median
+189% vs market
20212025
Asset turnover
2.79×
This company
1.12×
Market median
+149% vs market
20212025
Debt / equity
0.49×
This company
0.62×
Market median
+21% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
DT Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50% | 50% | 2024 | |
| Company | 24.5% | 24.5% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
You Learn As
NATURE PHARMA NORGE AS Board members of NATURE PHARMA NORGE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dag Tore Skjøthaug | Chief Executive Officer | 0 companies |
| Terje Andre Skulbru | Chairman | 0 companies |
| Daniel Helmut Podpeskar-Johansen | Board of Directors | 0 companies |